Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6840630 | 0.88 | CASP3 (0.55) | MAOBMAOAPTPN1TBK1HTT | |
| SCHEMBL874939 | 0.86 | ALDH1A1 (0.56) | MAOBMAOAPTPN1HTTALDH1A1 | |
| SCHEMBL3350981 | 0.82 | MAOB (0.65) | MAOBMAOAPTPN1HTTALDH1A1 | |
| SCHEMBL26054504 | 0.82 | PTPN1 (0.51) | MAOBMAOAPTPN1HTTALDH1A1 | |
| SCHEMBL11513004 | 0.81 | MAOB (0.67) | MAOBMAOAHTTALDH1A1KDM4E | |
| SCHEMBL4576015 | 0.81 | MAOB (0.61) | MAOBMAOAPTPN1HTTALDH1A1 | |
| SCHEMBL31723115 | 0.81 | MAOB (0.61) | MAOBMAOAPTPN1HTTALDH1A1 | |
| SCHEMBL11510079 | 0.78 | MAOB (0.67) | MAOBMAOAPTPN1TBK1ALDH1A1 | |
| SCHEMBL23320560 | 0.78 | KDM4E (0.50) | MAOBMAOAHTTALDH1A1GRIN1 | |
| SCHEMBL31704456 | 0.78 | KDM4E (0.50) | MAOBMAOAHTTALDH1A1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | claimed |
| US-12329755-B2 | Bromodomain inhibitors to target therapy-resistant cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-17 | — | — | US | disclosed |
| CN-117024390-A | Cdc20 small molecule ligand compound and application of degradation agent thereof | 中国海洋大学 | 2023-11-10 | — | — | CN | disclosed |
| US-20220296592-A1 | BROMODOMAIN INHIBITORS TO TARGET THERAPY-RESISTANT CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2022-09-22 | — | — | US | disclosed |
| WO-2021041801-A1 | BROMODOMAIN INHIBITORS TO TARGET THERAPY-RESISTANT CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| US-4320133-A | Penicillins and their antibacterial use | SANDOZ LTD. (CH) | 1982-03-16 | — | — | US | disclosed |
| EP-0003115-A1 | Penicillins, per se and for use as antibacterially active antibiotics and their production | SANDOZ AG (CH) | 1979-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | MAOB 103/4885MAOA 234/4885PTPN1 3619/4885 |
| US-20220296592-A1 | BROMODOMAIN INHIBITORS TO TARGET THERAPY-RESISTANT CANCER | BRD1, SMARCE1, SMARCA1 | MAOB 4607/4885MAOA 4554/4885PTPN1 4458/4885 |
| US-12329755-B2 | Bromodomain inhibitors to target therapy-resistant cancer | BRD1, SMARCE1, SMARCA1 | MAOB 4607/4885MAOA 4554/4885PTPN1 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.